Series E Funded Health Care Startups
Series E rounds in this Health Care set span from 2021-04-07 (PharmEasy, $323M) through 2025-01-15 (Owlstone Medical, $27M).
Series E rounds in this Health Care set span from 2021-04-07 (PharmEasy, $323M) through 2025-01-15 (Owlstone Medical, $27M). The disclosed-size distribution is highly uneven: PharmEasy’s $323M is the only disclosed round above the $150M level (next-highest Omada Health at $192M on 2022-02-23, with Virta Health at $133M on 2021-04-19 and Imperative Care at $150M on 2024-07-25). A clear temporal cluster also appears in 2022: four of the 12 rows (Visby Medical $35M on 2022-06-29, MicroTransponder $53M on 2022-06-20, Omada Health $192M on 2022-02-23, EGYM $41M on 2021-09-16 is outside that cluster but anchors 2021–2022) fall in 2022, concentrating deal activity relative to 2024 where five entries land between 2024-01-03 and 2024-11-18.
Geographically, the list is weighted toward the United States and includes multiple recurring metros: San Francisco appears for Omada Health ($192M on 2022-02-23) and Virta Health ($133M on 2021-04-19), while the Bay Area also shows up with San Jose (Visby Medical, $35M on 2022-06-29). The smallest disclosed amount is NephroPlus at $24M on 2021-12-13, noticeably below the rest of the range (with most rounds between $35M and $65M).
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed Series E round here, and how does it compare to the rest of the list?
PharmEasy’s $323M disclosed round on 2021-04-07 is the standout outlier. The next-largest disclosed amount is Omada Health at $192M on 2022-02-23, while Virta Health ($133M on 2021-04-19) and Imperative Care ($150M on 2024-07-25) sit below that tier.
Are these Series E closures clustered in time, or spread evenly across the years shown?
The most visible clustering is in 2024 and 2022. In 2024, five entries fall between 2024-01-03 (Nalu Medical, $65M) and 2024-11-18 (Quanta, $60M); in 2022, three entries concentrate between 2022-02-23 (Omada Health, $192M) and 2022-06-29 (Visby Medical, $35M), with MicroTransponder ($53M on 2022-06-20) adjacent.
Which cities show up repeatedly, suggesting a geographic concentration?
San Francisco is repeated for Omada Health ($192M on 2022-02-23) and Virta Health ($133M on 2021-04-19). California also appears multiple times beyond San Francisco: San Jose (Visby Medical, $35M on 2022-06-29) and San Francisco’s broader Bay Area footprint is reinforced by San Jose plus the Dallas and Houston entries (MicroTransponder and Procyrion, respectively).
Which outliers are worth closer attention besides the largest round?
The low-end outlier is NephroPlus at $24M on 2021-12-13, substantially below the rest of the disclosed range. On the high side, Omada Health’s $192M on 2022-02-23 is also a notable upper-tail value even though it is far below PharmEasy’s $323M.
How much of this list sits in the most recent window of the rows shown?
Within roughly the most recent year, multiple entries appear: Quanta ($60M on 2024-11-18), Imperative Care ($150M on 2024-07-25), Procyrion ($48M on 2024-02-05), and Nalu Medical ($65M on 2024-01-03), plus Owlstone Medical ($27M on 2025-01-15). That makes at least five of the 12 rows dated from 2024-01-03 onward.
Does the list show a consistent size band, or are amounts spread across very different ranges?
Amounts are spread but with concentration in the middle: several deals land in the $35M–$65M band, including Visby Medical ($35M on 2022-06-29), Owlstone Medical ($27M is below), Procyrion ($48M on 2024-02-05), MicroTransponder ($53M on 2022-06-20), Quanta ($60M on 2024-11-18), and Nalu Medical ($65M on 2024-01-03). The distribution is lifted by the top tail—Imperative Care ($150M on 2024-07-25), Virta Health ($133M on 2021-04-19), Omada Health ($192M on 2022-02-23), and PharmEasy ($323M on 2021-04-07).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.